Pembrolizumab Combined With GDP Regimen Inducing Sustained Remission in Histiocytic Sarcoma: A Case Report.
J Investig Med High Impact Case Rep
; 12: 23247096241274561, 2024.
Article
in En
| MEDLINE
| ID: mdl-39215504
ABSTRACT
Histiocytic sarcoma (HS) is a rare hematopoietic neoplasm with an aggressive clinical course and a poor response to conventional chemotherapy. Currently, no standard treatment paradigms are available. Herein, we present a case of de novo HS treated with pembrolizumab combined with a GDP regimen (gemcitabine, cisplatin, and dexamethasone) that resulted in sustained complete remission with progression-free survival exceeding 4 years. Immunohistochemical analysis demonstrated significant overexpression of programmed death ligand 1 (PD-L1) on biopsy samples. Additionally, fluorescence in situ hybridization (FISH) with a JAK-2 probe indicated 9p24.1 amplification, suggesting reliance on the JAK-STAT pathway. Polymerase chain reaction (PCR) analysis did not reveal any BRAF-V600 mutations. Consequently, an immune checkpoint inhibitor (ICI) was administered alongside chemotherapy, resulting in sustained complete remission and progression-free survival for over 4 years. Our findings suggest that a combination of ICI and chemotherapy could represent a promising therapeutic approach for HS.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Dexamethasone
/
Antineoplastic Combined Chemotherapy Protocols
/
Cisplatin
/
Deoxycytidine
/
Histiocytic Sarcoma
/
Antibodies, Monoclonal, Humanized
/
Gemcitabine
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Investig Med High Impact Case Rep
/
J. Investig. Med. High Impact Case Rep
/
Journal of investigative medicine high impact case reports
Year:
2024
Document type:
Article
Affiliation country:
China
Country of publication:
Estados Unidos